Key Portfolio Companies
Spinefrontier is an example of our imitate with patented improvements strategy. Founded in 2006, because Dr. Chin invented the Less Exposure Surgery (LESTM) Philosophy to improve on Minimally Invasive Surgery (MIS) techniques. Today, we have +25 FDA cleared products with +40 issued patents worldwide. The company is revenue generating since 2007 and profitable since 2011 with current distribution across the United States and South America.
AxioMed is an example of our disruptive innovation strategy. We acquired AxioMed in 2014 from previous owners that had raised +$75M from nine venture capital firms with a Lumbar Disc near completion of the US IDE and a Cervical Disc with a completed European pre-clinical IDE. It is universally accepted that the AxioMed disc will disrupt the current fusion paradigm and immediately replace the current rudimentary ball and socket disc designs on the market. We have now completed the landmark US IDE for the Lumbar Disc with over 5 years of clinical follow-up. We have developed the protocol to start the US Cervical Disc IDE seeking FDA clearance for up to 3-levels and hybrid adjacent to fusion. We are leveraging our experience from the Lumbar IDE Study to complete this game changing Cervical IDE Study. In the meantime, we expect to release the Lumbar Disc in the US by 2020 and hope to achieve a lateral indication. We have set a target of combined global revenues of $250M per year by 2023.
NanoFUSE® is an example of our disruptive innovation strategy. We acquired NanoFuse in 2018 because of its unique product line. It is based on a patented manufacturing process for bioactive glass. It is also the only company to have an FDA cleared combination of Synthetic Bioactive Glass and Organic Biologics (Demineralized Bone Matrix) that can be broadly used across all orthopedic and spine applications. Any competitor would need to develop a product and take it through the arduous IDE process to obtain US FDA clearance. The company is revenue generating with current distribution in the United States and select markets overseas.
The LESS Institute is an example of our imitate with patented improvements strategy. In 2006, Dr. Chin conceived the LES® treatment philosophy and embarked on applying it to develop technologies as well as surgical techniques. In order to practice these techniques, he developed the LESS Institute in 2008 to treat patients with this LES philosophy with a plan to build a professional group and LES specialty treatment centers of excellence. Dr. Chin felt MIS was difficult to implement with disadvantages so the LES philosophy is an improvement. The LESS Institute also sees the opportunity to improve on hospitals by decreasing size and operating costs and developing specialty centers focused on neurosurgery, spine and orthopedics. The company is revenue generating and profitable and has begun its international expansion strategy.
Investor Opportunites Available Now
© Copyright 2018. All Rights Reserved.